APOS Therapy for Knee Osteoarthritis

Knee osteoarthritis (OA) is a leading cause of pain, disability, and reduced quality of life worldwide, particularly among older adults. Affecting roughly 50% of people over 65, it involves progressive cartilage degradation, bone remodeling, and inflammation, often exacerbated by abnormal biomechanics and gait patterns. Traditional treatments range from conservative options like physical therapy, weight loss, and analgesics to invasive procedures such as total knee replacement (TKR). In recent years, APOS Therapy (also known as Apos® or AposTherapy) has emerged as a non-invasive, biomechanical intervention that addresses underlying gait and load-distribution issues. This essay explores the mechanism, clinical evidence, benefits, limitations, and future potential of APOS Therapy in managing knee OA.

APOS Therapy utilizes a personalized, foot-worn biomechanical device consisting of a shoe-like platform with two adjustable, convex pods attached to the sole. Trained physiotherapists calibrate the pods' position and size based on the patient's gait analysis, symptoms, and physical examination. This customization manipulates the foot's center of pressure (COP) and alters the ground reaction force (GRF) vector, effectively shifting load away from the damaged knee compartments—often the medial side in varus-aligned knees. Simultaneously, the convex pods introduce controlled micro-instability or perturbation during walking. This challenges neuromuscular control, promoting muscle strengthening, improved proprioception, and gait retraining. Patients typically wear the device for 1–3 hours daily during routine activities, allowing integration into daily life without dedicated exercise sessions. The goal is immediate pain relief through load redistribution plus long-term carry-over effects from neuromuscular adaptation, so patients walk more naturally even without the device.

The biomechanical rationale is compelling. Knee OA is strongly linked to elevated knee adduction moments (KAM) and improper joint loading during gait. By realigning the GRF closer to the knee's center, APOS reduces these moments, decreasing stress on articular cartilage and subchondral bone. Studies demonstrate reductions in KAM and knee flexion moments, alongside improved spatiotemporal gait parameters such as step length and velocity. This dual action—immediate unloading and ongoing training—distinguishes APOS from standard orthotics or footwear.

Clinical evidence supporting APOS Therapy is robust and growing. Early prospective studies, such as those by Elbaz et al. (2010), reported significant improvements in pain, function, and gait patterns after 12 weeks. Patients showed better clinical measurements and walking mechanics. A 2013 long-term study by Bar-Ziv and colleagues found sustained pain reduction and functional gains over extended periods.

A landmark 2020 randomized controlled trial (BIOTOK) published in *JAMA* provided high-level evidence. In 220 participants with knee OA, individualized biomechanical footwear (APOS) was compared to control footwear. At 24 weeks, the APOS group achieved a significantly greater reduction in WOMAC pain scores (from 4.3 to 1.3 vs. 4.0 to 2.6 in controls; between-group difference -1.3, p

Craig Payne is a University lecturer, runner, cynic, researcher, skeptic, forum admin, woo basher, clinician, rabble-rouser, blogger and a dad.